Bayer has agreed a deal with Foundation Medicine to develop test kits which can be used to identify patients for its Vitrakvi cancer therapy. The kits will use the genetic sequencing of tumour cells to find individuals who will benefit from the drug, which research shows is capable of shrinking tumours from 24 different types of cancer in about 1 percent of patients.
Bayer has agreed a deal with Foundation Medicine to develop test kits which can be used to identify patients for its Vitrakvi cancer therapy. The kits will use the genetic sequencing of tumour cells to find individuals who will benefit from the drug, which research shows is capable of shrinking tumours from 24 different types of cancer in around 1% of patients.